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Abstract The incidence of inflammatory bowel diseases
(IBD), as well as other inflammatory conditions, has dra-
matically increased over the past half century. While many
studies have shown that IBD exhibits a genetic component
via genome-wide association studies, genetic drift alone
cannot account for this increase, and other factors, such as
those found in the environment must play a role, suggesting
a ‘‘multiple hit’’ phenomenon that precipitates disease. One
major environmental factor, dietary intake, has shifted to a
high fat, high carbohydrate Western-type diet in develop-
ing nations, nearly in direct correlation with the increasing
incidence of IBD. Recent evidence suggests that specific
changes in dietary intake have led to a shift in the com-
posite human gut microbiota, resulting in the emergence of
pathobionts that can thrive under specific conditions. In the
genetically susceptible host, the emerging pathobionts can
lead to increasing incidence and severity of IBD and other
inflammatory disorders. Since the gut microbiota is plastic
and responds to dietary modulations, the use of probiotics,
prebiotics, and/or dietary alterations are all intriguing
complementary therapeutic approaches to alleviate IBD
symptoms. However, the interactions are complex and it is
unlikely that a one-size-fits all approach can be utilized
across all populations affected by IBD. Exploration into
and thoroughly understanding the interactions between host
and microbes, primarily in the genetically susceptible host,
will help define strategies that can be tailored to an indi-
vidual as we move towards an era of personalized medicine
to treat IBD.
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Introduction
The prevalence of ‘‘New age’’ Western disorders has
increased dramatically worldwide over the past half-cen-
tury, including obesity, diabetes, colorectal cancer, and
inflammatory bowel diseases (IBD) [1–4]. The Centers for
Disease Control and Prevention reports that, in the United
States alone, 1/3 of adults are obese while 1.4 million
adults suffer from IBD [4, 5]. The battle over why these
diseases are on the rise continues to be a topic of debate,
but in the advent of new technological advances to probe
these questions, recent studies are emphasizing the com-
plexity of these disorders while also bringing to light new
avenues to treat them from both a prophylactic and thera-
peutic perspective.
Inflammatory bowel diseases, both Crohn’s Disease
(CD) and Ulcerative Colitis (UC) are complex immune
disorders that clearly exhibit a genetic basis [6, 7]. Gen-
ome-wide association studies (GWAS) have shown that
many genes correlate with the development of CD and UC,
however, not every individual presenting with genetic
abnormalities will develop disease. This prevents GWAS
to predict development and also emphasizes that genetics
alone cannot account for the propensity of an individual to
develop CD or UC. Other factors, such as environmental
triggers (i.e., NSAIDs, smoking, and diet) must play a role
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[8]. Indeed, dietary intake in Western populations has
dramatically shifted to a high-fat, high carbohydrate diet
over the past-half century, nearly in concordance with the
development of disease [9]. These dietary alterations have
resulted in a shift in the composite gut microbiota, from
both a structure (taxonomy) and function (metagenomic)
perspective, that have been shown to play a role in complex
disorders such as IBD in both human and animal studies
[10–16]. Gut bacteria outnumber human cells by nearly
10-fold and contain an estimated 1,000,000? genes
(whereas humans contain only 23,000) [17, 18]. This
highlights that while genetic mutations in the human gen-
ome can be associated with IBD development, gut bacteria
and their functions cannot be ignored as major players in
disease. The combination of genetic predisposition coupled
with environmental factors that shift the gut microbiota can
result in the ‘‘perfect storm’’ leading to IBD development.
Genetics and environment in IBD etiopathogenesis
Clinical observations of patients presenting with CD or UC
suggest that genetics play a role in development of disease.
Prevalence of either CD or UC varies among different
populations, while a positive family history is exhibited
amongst first-degree relatives in 6–22 % of affected
patients [19]. A greater concordance of IBD has been
identified among monozygotic rather than dizygotic twins
and syndromes resembling IBD co-segregate in families
with rare genetic disorders [20]. Lastly, concordance is
exhibited in the type and site of disease among families
with multiple affected members [6, 7]. However, genome-
wide searches for IBD susceptibility loci have provided the
most convincing evidence of a genetic link, identifying 47
risk alleles in UC and 71 in CD [21].
One gene for which SNP’s have consistently been asso-
ciated with CD risk is the nucleotide-binding oligomeriza-
tion domain containing 2 (NOD2 also called CARD15) gene
located on chromosome 16. The gene is expressed as a
cytoplasmic protein that recognizes muramyl dipeptide, a
component of bacterial cell wall peptidoglycan [22]. Thus,
the NOD2 protein is important in the discrimination between
normal intestinal flora and pathogenic bacteria. Pattern rec-
ognition by NOD2 initiates the signal transduction that leads
to translocation of NFjB to the nucleus, transcription of
specific genes and activation of appropriate innate and
adaptive immune responses [22]. The most common sus-
ceptibility allele is 3020insC, which encodes a truncated
NOD2 protein lacking the last 33 amino acids, and shows
association with CD risk both by itself and in combination
with SNPs in other genes [23, 24]. While heterozygote
individuals are also at increased risk, NOD2 homozygous
individuals may have a 20-fold or more increase in
susceptibility to CD, with a particular susceptibility for ileal
disease [25]. However, fewer than 20 % of patients with CD
are homozygous for NOD2 variants. Since the discovery of
NOD2, several additional susceptibility loci have been
implicated in IBD: IBD5, IL23R and ATG16L1 [26–28].
While GWAS have provided important insight into the
pathogenesis of IBD, NOD2 mutations, for example, only
account for 25 % of CD cases in Caucasians, and is not
implicated in the pathogenesis of UC. Furthermore, these
genetic discoveries do not explain the variation in inci-
dence between different populations or the rising incidence
of disease in industrialized countries over the past 50 years
[4]. These clues suggest environmental, and perhaps even
epigenetic factors, are playing an increasing role in the
pathogenesis of IBD. Together, this points to a ‘‘multiple-hit’’
hypothesis in which a genetically susceptible individual
encounters a single or series of environmental triggers, which
tip the scale of a compensated immune response in favor of
dysregulated inflammation.
Gut microbiota and IBD
Among these critical environmental encounters forming a
second or third hit is dietary intake. Evolution, acting through
natural selection, represents an ongoing interaction between a
species’ genome and its environment over the course of
multiple generations. When the environment remains rela-
tively constant, stabilizing selection tends to maintain genetic
traits that represent the optimal average for a population.
However, as environmental conditions change, evolutionary
discordance arises between a species’ genome and its envi-
ronment. Stabilizing selection is replaced by directional
selection, moving the average population genome to a new
set point [29, 30]. Initially, when environmental changes
occur in a population, individuals possessing the previous
average genome experience evolutionary discordance [31].
In the affected genotype, this discordance manifests itself
phenotypically as disease, increased morbidity and mortality,
and reduced reproductive success. There is now growing
awareness and evidence that the profound environmental
changes in diet that began with the introduction of agriculture
and animal husbandry 10,000 years ago occurred too
recently on an evolutionary time scale for the human genome
to adapt [32, 33]. In conjunction with this discordance
between our ancient, genetically determined biology and the
nutritional patterns in contemporary Western populations,
particularly of the last 50 years, many of the so-called dis-
eases of civilization have emerged [33, 34].
Our human physiology is not the only entity that has
been challenged by changes in dietary practices- the tril-
lions of microbes that live within our intestinal bioreactor
have also been forced to adapt. In many cases, these
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adaptations have not been favorable, and provide yet an
additional ‘‘hit’’ in the multi-hit theory influencing the
incidence of IBD in genetically susceptible individuals and
populations (Fig. 1).
Our enteric microflora interacts intimately with our
intestinal mucosa and thus is both essential for metabolizing
nutrients that we have not evolved to digest on our own, as
well as for maturation and education of intestinal immune
cells [35]. The metabolic mutualism between host and
microbe, when chronically disrupted, can result in aberrant
immune responses leading to disease [36]. Gut microbes
can stimulate immune responses either by functioning as
adjuvants or antigens. As adjuvants they activate innate
immune responses, including dendritic cells and other
APCs, and as antigens they stimulate the clonal expansion
of T cells that selectively recognize the antigen through
their T cell receptor. For example, genetically susceptible
hosts, including IBD patients, and genetically engineered
mice with spontaneous mutations have aggressive T cell
responses to luminal commensal bacteria [37, 38]. Although
B cell responses to enteric microbial constituents are
exaggerated in CD, UC, as well as in experimental intestinal
inflammation, antibodies are not necessary to transmit dis-
ease in experimental colitis, and B-lymphocytes seem to be
regulatory rather than pathogenic [39, 40]. Antibodies to
bacteria have, therefore, been primarily useful as part of
diagnostic tests and could potentially identify clinically
important subsets of IBD patients who have selective
responses to therapeutic agents and have predictable natural
histories [41].
Studies of antigen specificity in IBD patientsare lacking,
yet several mouse models of disease have provided great
insight into the interplay between genetics and environ-
mental factors that contribute to the development of IBD.
Experiments in animal models have shown that disease can
be transferred to immunodeficient hosts (such as T cell-
deficient severe, combined immunodeficient (SCID),
Rag-/- mice, as well as nude rats) via T cells that respond
to commensal enteric bacteria. Cong et al. [42] demon-
strated that T cell clones that respond to cecal bacterial
lysates transfer colitis to SCID mice, but that nonspecifi-
cally activated T cells do not. Since then, they have also
demonstrated that flagellin-specific T cell clones can
transfer colitis to SCID mice [37].
In over 12 different animal models, colitis and immune
activation fail to develop in the absence of commensal
bacteria. Additional studies have demonstrated both bac-
terial species and host specificity for the induction of
experimental colitis. Studies utilizing the IL-10 deficient
mouse (IL-10-/-), regardless of background strain, have
shown that development and severity of spontaneous colitis
is dependent upon the milieu of the enteric gut microbiota
Fig. 1 Intake of Western high fat-high carbohydrate diet promotes
expansion of pathobionts in the GI tract, resulting in decreased
abundance of commensals. Metabolism of the emerging pathobionts
leads to increased host exposure to detrimental bacterial products (i.e.,
H2S) and reduced exposure to beneficial products, such as short chain
fatty acids (SCFAs). This results in increased immunogenic antigen
exposure, prompting inflammatory cytokine production of both
antigen-presenting cells (i.e., IL-12p40) and T cells (i.e., IFN-
gamma) that increase intestinal inflammation
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[43, 44]. Penetrance of colitis rises to nearly 100 % in these
mice when the enteric microbiota contains Helicobacter
hepaticus and is defined by a T-helper 1 (Th1) IFN-gamma
response [44]. However, when IL-10-/- mice are main-
tained under germ-free conditions, this mouse does not
develop spontaneous colitis [36, 43].
Even in this spontaneous model of colitis, disease
can manifest differentially based on the gut bacteria
present. Monoassociation of germ-free IL-10-/- mice with
the commensal bacteria Bilophila wadsworthia or E. coli
induces phenotypically distinct forms of colitis [45].
B. wadsworthia induces an intermediate onset of colitis
(3–5 weeks after bacterial colonization) and involves the
distal colon, with low-grade colitis accompanied by an
exclusively Th1-mediated immune response. Interestingly,
the colitis is much more severe when this bacterium blooms
in the presence of other bacteria (i.e., specific pathogen free
IL-10-/- mice) [36]. In contrast, E. coli monoassociation
leads to relatively early (3 weeks) onset of a mild-to-mod-
erate inflammation that is most severe in the cecum [45].
Preliminary studies show that Klebsiella monoassociation
induces moderate pan-colitis and Bifidobacterium animalis
monoassociation leads to distal colonic and duodenal
inflammation [46, 47]. These results demonstrate that even
a traditionally probiotic bacterial species can induce
inflammation in a susceptible host, raising concern over the
safety of probiotic therapy in some patients.
Gut microbiota: therapeutic potential
The requirement for host specificity is demonstrated by the
variable responses to three unique bacterial species in three
different models of colitis: B. wadsworthia and E. coli both
increase the incidence of colitis in monoassociated IL-
10-/- mice, but Bacteroides vulgatus, for example, does
not. In contrast, B. vulgatus, but not E. coli, induces colonic
inflammation in HLA-B27 transgenic rats, and neither
causes disease in bone-marrow-transplanted CD3 trans-
genic mice [45]. Similarly, various probiotic species elicit
varying results in the same host, while different hosts
respond variably to the same probiotic species [48]. These
studies suggest that the disease risk and phenotypes in a
single host are highly dependent on the composition of
microbiota in the context of different genetic backgrounds.
Implied from these observations is the likelihood that
personalized therapies for individuals will have to be
designed, based on host genetics, biological responses, and
gut microbial functional profiles.
In addition, dietary components may become a com-
plementary element of personalized therapies. We know
that particular dietary components can alter the composi-
tion and virulence of commensals; as stressed earlier, this
may provide one potential explanation for the marked
increase in the incidence of IBD (and other ‘‘New Age’’
disorders) in Western countries over the last 50 years, and
more recently in Eastern countries, as they adopt Western
dietary practices [4]. Increased fat consumption is a hall-
mark of Western dietary practices and has been linked to
increased prevalence of IBD. However, many of these
studies have only examined the total amount of fat in the
diet rather than the fat source. Devkota et al. [36] dem-
onstrated that the type of dietary fats can dramatically
reshape the gut microbiota, which can shift the balance of
host-microbe interactions in ways that perturb immune
homeostasis in genetically-prone individuals and trigger
the onset of colitis. The study showed that only the milk
fat-based saturated fat diet precipitated disease in geneti-
cally susceptible IL-10-/- mice by inducing a bloom of the
pathobiont B. wadsworthia. However, this finding should
not be taken out of this rigorously defined experimental
context to suggest that high dietary consumption of milk fat
precipitates disease in every individual. The caveat is that
environmental and dietary triggers for individuals are
highly variable and depend on convergence of numerous
factors. A diet high in milk fat in one person may not be the
triggering factor for another. The recognition that ‘‘New
Age’’ disorders come about by multiple-hit events under-
scores the importance of personalized medicine in the
future where combinatorial factors can be used to assess
risk in genetically susceptible individuals.
Similarly, studies have shown that non-absorbed car-
bohydrates (prebiotics) such as inulin and fructooligosac-
charides enhance the growth of beneficial Bifidobacterium
and Lactobacillus species providing a substrate for the
production of short-chain fatty acids (SCFAs) by these
bacterial species. The SCFA’s, especially butyrate, are the
preferred metabolic substrates of colonocytes, and can
stimulate various mucosal barrier functions [46]. Indeed, a
study examining twin pairs, with one healthy twin and one
with CD showed that metagenomic and metaproteomic
potential was altered in the afflicted twins. Here, reduced
diversity was coupled with a reduction in several functional
pathways, including carbohydrate metabolism. More spe-
cifically, those enzymatic pathways involved in complex
carbohydrate metabolism that would result in SCFA pro-
duction were diminished. In addition, pathways involved in
mucin degradation were also decreased in CD patients,
indicating that the potential to breakdown oligosaccarhides
is diminished during CD [49]. Additionally, a study using
methods to predict function via 16s rRNA analyses and
validated by shotgun metagenomics on a subset of samples
also noted a reduction in pathways involved in SCFAs in
CD patients when compared to healthy controls [50].
Morgan et al., correlated their predicted bacterial function
analyses to recorded environmental metadata (including
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smoking and antibiotic/anti-inflammatory drug usage), in
patients versus controls, however, neither of these studies
tracked dietary intake of these patients and their respective
controls. Therefore, interpretation of the effects of CD
versus dietary intake or their interaction is difficult.
Regardless of the lack of dietary correlations, it would
seem that CD patients might benefit from a re-shaping of
their gut microbiota to promote metabolic pathways that
would increase SCFAs. However, these types of therapies
may not benefit all individuals, and clinicians must begin to
think about treating IBD at the individual level rather than
at a one-size-fits-all level in order to specifically tailor their
recommendations.
There is now compelling data to suggest genetically
susceptible hosts who are unable to clear an invading
pathogen and/or generate tolerogenic immune responses to
commensal microbial agents proceed to chronic, relapsing
intestinal inflammation. Resistance to T cell apoptosis, lack
of response to downregulatory signals, as well as continu-
ous exposure to luminal antigens and adjuvants help sustain
this inflammatory response. It is very likely that environ-
mental factors such as diet may, in turn, profoundly affect
mucosal immune responses and enteric bacterial popula-
tions. In addition, in an experimental setting utilizing mouse
models of intestinal inflammation, dietary variation can be
carefully controlled, and generally, only one aspect of
dietary intake (fat, carbohydrate, or protein) will be modi-
fied in a given experiment. Many interactions between
dietary components can be missed, especially in the context
of the gut microbiota. It is therefore unlikely that one die-
tary modification will alleviate all symptoms of IBD, and
other factors (i.e., lifestyle, medications, etc.) should also be
considered. However, once these interactions have been
clearly defined and mechanistically described using a
variety of human and mouse models of intestinal inflam-
mation, these concepts can be utilized in the clinic as
alternative and complementary approaches to prevent/treat
IBD, even in the face of Western diets that negatively shift
gut bacteria in the genetically susceptible host (Fig. 2).
Conclusions
The impact of Western diets on gut microbiota and disease
outcomes has become increasingly recognized and may
account for the observed rising trends in disorders, such as
IBD, over the past half century. In the advent of non-cul-
ture based techniques to study the gut microbiota, the
Fig. 2 Microbiota-centric therapeutic strategies, including prebiotics,
probiotics, or dietary modulation can promote an increase in short
chain fatty acid (SCFA) production even in the context of a Western
diet. These therapies may restore commensal microbiota and diminish
pathobionts. The therapeutic strategies may restore immune balance,
promoting anti-inflammatory properties (such as T-regulatory cell
function) leading to a decrease of intestinal inflammation in the
genetically-susceptible host
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intricate interplay between host genetics and the metage-
nomic/functional potential of the bacteria can be both
explored and exploited. The knowledge gained through
further inquiry into the interactions between the host, the
environment, and the gut bacteria will help us understand
the importance of environmental factors, particularly die-
tary trends, on human health as they pertain to IBD
patients. These concepts can serve as a basis for formu-
lating both prophylactic and therapeutic approaches that
are feasible and acceptable to the general population in the
era of personalized medicine.
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